udy Design and Implementation

SM

How patients are becoming active participants in the clinical decision-making process .

What is the MMRF CoMMpass Study ?

The MMRF CoMMpass Study SM is about patients helping patients to put new treatment options within reach . By providing their bone marrow samples when first diagnosed , and continuing to do so for at least eight years , patients are enabling researchers to track how multiple myeloma progresses , changes and reacts to treatments over time . Led by the MMRF and launched in 2011 , the MMRF CoMMpass Study ( Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profiles ) is the first large-scale , longitudinal study in multiple myeloma . It is a $ 40 million effort funded by the MMRF in conjunction with our pharmaceutical partners .

The MMRF CoMMpass Study consists of patients , 18 years or older , who were candidates for an immunomodulatory drug ( e . g ., Revlimid ® [ lenalidomide ], Pomalyst ® [ pomalidomide ] or Thalomid ® [ thalidomide ]) and / or a proteasome inhibitor ( e . g ., Velcade ® [ bortezomib ] or Kyprolis ® [ carfilzomib ]) as part of their initial treatment regimen .

In 2015 , the CoMMpass Study reached its target enrollment of 1,000 multiple myeloma patients , a remarkable achievement for a relatively rare disease , and a testament to the commitment of patients to help advance the study of multiple myeloma . The MMRF CoMMpass Study involves an active assessment schedule including bone marrow samples when first diagnosed to establish a baseline , at response to treatment , and at relapse . Each patient is followed for up to eight years and their data is analyzed every six months . Any new insights that can help their treatment are brought to the patient by their doctor .

Today , the MMRF CoMMpass Study is in 100 sites across the U . S ., Canada and European Union , and involves nonprofit , industry , and academic partners . While participating institutions have prioritized access to the data they collect for an initial period of time , they have all agreed to put it in the public domain . Creating this intellectual property-free zone enables multiple constituents to collaborate on data analysis and sharing initiatives — essentially breaking down the data silos that impede research today . The benefit to patients is that it accelerates the pace of research and brings new treatments to them as quickly as possible .

400 200

0

8 Patients Enrolled October 2011

180 Patients Enrolled

425 Patients Enrolled

2011 2012 2013 2014 2015

6 THEMMRF . ORG